Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aduhelm Looks Set For Rejection In Europe For Alzheimer's

Adds To US Woes

Executive Summary

The EMA’s likely rejection is no surprise for Biogen and Eisai, but adds to problems in the same week as Biogen’s R&D leader announced his departure.

You may also be interested in...



Aducanumab: Biogen Is The Latest Firm To Preempt A Negative EU Opinion On Approval

The EU marketing application for aducanumab is heading for a rejection for Alzheimer’s disease, according to a “negative trend vote” at the CHMP disclosed by the drug’s sponsors.

The Architect Of Biogen's Controversial Alzheimer's Strategy, Al Sandrock, To Retire

Despite 23 years at Biogen assisting in the development of several drugs, Sandrock's legacy will be tied to Alzheimer’s drug Aduhelm.

Biogen’s Q3 Aduhelm Sales Even Worse Than Expected

Analysts expected at least $12m in third quarter sales, but the Alzheimer’s therapy brought in just $300,000. The company says educating doctors and procuring a coverage determination from CMS – not lower pricing – are key to growth.  

Topics

Related Companies

UsernamePublicRestriction

Register

SC145431

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel